secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-08-13T20:25:23+00:00
Accession:  0001213900-26-089137
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Q2 2026: cash $1.02B, net loss $40.6M, Phase 3 ZENITH AD initiated
-------------------------------------------------------------------------

- Cash and investments $1,023.4M at June 30, 2026 vs $245.8M at Dec 31, 2025; runway into Q3 2028.
- Q2 revenue $10.1M (vs $11.2M); net loss $40.6M ($1.23/share) vs $41.6M ($2.95/share) year-ago.
- R&D expense $39.1M (up from $29.9M) on Phase 3 ZENITH AD and manufacturing; G&A down to $12.8M.
- Initiated first two Phase 3 ZENITH AD trials in atopic dermatitis in July 2026; BLA submission planned 2029.
- April 2026 offering raised $373.8M gross; positive 52-week REZOLVE-AA results announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390026089137/0001213900-26-089137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390026089137/ea0301929-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-089137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer